WAVE.V -- Bottoming Out Undervalued Pharma/COVID-19 Play
已更新
The most attractive part of WAVE.V is share structure: 54M total float with 41M shares held by insiders / escrowed, leaving about 13M shares free trading. The company owns a portfolio of generic oncology drugs from which it generates over 300K of quarterly revenue. 
1M in cash on hand. Based on last financials, they are 883K away from generating positive cash flow and recent developments suggest they will get there sooner rather than later:
-- Received grant to develop a rapid COVID-19 saliva based test in partnership with the University of Manitoba
-- Received authorization from several EU countries to expand sales of their generic oncology drugs
-- Expecting FDA authorization in Q4 2020
At below 10M mkt cap and in the absence of any cheap paper overhang, I feel that this is a tremendous opportunity. Compare it to something like THRM.V which is developing a similar saliva-based COVID-19 test, has next to nothing in revenues, a ton of cheap paper, 3x the float and 3x the market cap, and you realize that current valuation makes no sense.
Chart suggests the stock is reversing from short term downtrend after finding bottom at .15. A doji, followed by green candle on increased volume and EMA 20 crossing above EMA 50 providing additional support at .16. Today was a pullback on lower volume that resulted in a higher low. I used it as an opportunity to pad my position.
Next catalysts that could propel sp to significantly higher levels are updates on the oncology drug sales in Europe, rapid COVID-19 test development progress and FDA approval of oncology drugs for sale/marketing in the US.
1M in cash on hand. Based on last financials, they are 883K away from generating positive cash flow and recent developments suggest they will get there sooner rather than later:-- Received grant to develop a rapid COVID-19 saliva based test in partnership with the University of Manitoba
-- Received authorization from several EU countries to expand sales of their generic oncology drugs
-- Expecting FDA authorization in Q4 2020
At below 10M mkt cap and in the absence of any cheap paper overhang, I feel that this is a tremendous opportunity. Compare it to something like THRM.V which is developing a similar saliva-based COVID-19 test, has next to nothing in revenues, a ton of cheap paper, 3x the float and 3x the market cap, and you realize that current valuation makes no sense.
Chart suggests the stock is reversing from short term downtrend after finding bottom at .15. A doji, followed by green candle on increased volume and EMA 20 crossing above EMA 50 providing additional support at .16. Today was a pullback on lower volume that resulted in a higher low. I used it as an opportunity to pad my position.
Next catalysts that could propel sp to significantly higher levels are updates on the oncology drug sales in Europe, rapid COVID-19 test development progress and FDA approval of oncology drugs for sale/marketing in the US.
注释
***Correction: The partnership with the University of Manitoba is for "Production of a Synthetic Library of Chloroquine Analogs and Precursors for Immediate and Future Development of COVID-19 Treatments" and not to develop a COVID-19 rapid test. Got it mixed up with my other holding IPA.V. It is late. :)注释
WAVE.V is finally breaking out of Cup & Handle pattern. 1.2M short positions need to cover and there are only 13M shares free trading. Insiders hold 75% of the float and their cost was .50! No warrants or cheap paper to hold this one down. Very interesting week coming up.交易结束：到达目标
相关出版物
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。